CClinicalTrials.gg
CompletedNCT07830875Updated Sep 23, 2026

Effect of Tranexamic Acid-Modified Leukocyte- and Platelet-Rich Fibrin on Hemostasis and Wound Healing After Tooth Extraction in Patients Receiving Direct Oral Anticoagulants

An interventional study of Tranexamic Acid-Modified L-PRF and Absorbable Gelatin Sponge in Patients Receiving Direct Oral Anticoagulants, sponsored by Cumhuriyet University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Cumhuriyet University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized split-mouth clinical study evaluated the effects of tranexamic acid-modified leukocyte- and platelet-rich fibrin (L-PRF) on hemostasis, postoperative pain, and soft-tissue wound healing after tooth extraction in patients receiving direct oral anticoagulants (DOACs). In each participant, extraction sites were allocated to either tranexamic acid-modified L-PRF or an absorbable gelatin sponge as a local hemostatic intervention. Hemostasis was assessed 30 minutes after extraction, postoperative pain was evaluated at 24, 48, and 72 hours, and soft-tissue wound healing was assessed on days 7, 14, and 21.

02

Conditions studied

  • Patients Receiving Direct Oral Anticoagulants

Keywords

  • Direct Oral Anticoagulants
  • Tooth Extraction
  • Tranexamic Acid
  • Leukocyte- and Platelet-Rich Fibrin
  • Hemostasis
  • Landry Wound Healing Index
  • Split-Mouth
  • Wound Healing
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥18 years
  • Receiving treatment with one of the specified direct oral anticoagulants (DOACs) for at least 2 months
  • No known hypersensitivity to the study materials
  • No diagnosis of malignant or premalignant lesions
  • Indication for extraction of at least two non-adjacent teeth

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate or inability/unwillingness to provide written informed consent
  • History of hypersensitivity or allergy to local anesthetics
  • Immunosuppression
  • Acute infection in any tooth planned for extraction
  • Treatment with antiresorptive medications
  • Essential or congenital coagulation disorders
  • Severe cirrhosis
  • Chronic kidney disease
  • Uncompensated diabetes mellitus
  • Uncontrolled hypertension
  • Pregnancy or breastfeeding
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    TXA-Modified L-PRF

    Participants received tranexamic acid-modified leukocyte- and platelet-rich fibrin (L-PRF) in the randomly allocated extraction socket as the local hemostatic intervention.

    Other: Tranexamic Acid-Modified L-PRF

  • Active comparator
    Absorbable Gelatin Sponge

    Participants received an absorbable gelatin sponge in the randomly allocated extraction socket as the local hemostatic intervention.

    Other: Absorbable Gelatin Sponge

Interventions

  • OtherTranexamic Acid-Modified L-PRF

    Participants received tranexamic acid-modified leukocyte- and platelet-rich fibrin (L-PRF) in the randomly allocated extraction socket. L-PRF was prepared from 8 mL of venous blood with the addition of 0.4 mL tranexamic acid (250 mg/5 mL) before centrifugation at 2700 rpm for 12 minutes. The resulting TXA-modified L-PRF was placed into the extraction socket as a local hemostatic intervention.

  • OtherAbsorbable Gelatin Sponge

    Participants received an absorbable gelatin sponge in the randomly allocated extraction socket as a local hemostatic intervention.

05

What researchers measure

Primary outcomes

  1. Soft tissue wound healing assessed using the Landry Wound Healing Index

    Soft tissue wound healing was assessed by a blinded examiner using the Landry Wound Healing Index. The index evaluates tissue color, suppuration, bleeding, granulation tissue, and connective tissue exposure. Healing was scored on a 1-5 scale: 1 = very poor, 2 = poor, 3 = good, 4 = very good, and 5 = excellent healing. Higher scores indicate better soft tissue healing.

    Time frame: 7, 14, and 21 days after tooth extraction

Secondary outcomes

  1. Postoperative hemostasis at 30 minutes

    Postoperative bleeding was assessed by a blinded examiner 30 minutes after placement of the final suture using a 0-5 clinical bleeding scale: 0 = no bleeding; 1 = minimal bleeding that stopped spontaneously; 2 = moderate bleeding controlled with simple pressure; 3 = marked bleeding potentially requiring medical intervention; 4 = uncontrolled bleeding potentially requiring serious medical intervention; and 5 = excessive, potentially life-threatening bleeding. Higher scores indicate greater bleeding severity.

    Time frame: 30 minutes after placement of the final suture

  2. Postoperative pain assessed using the Visual Analog Scale

    Postoperative pain was assessed using a 10-cm Visual Analog Scale (VAS), where 0 represents no pain and 10 represents the worst pain imaginable. Participants recorded pain intensity separately for the TXA-modified L-PRF and absorbable gelatin sponge extraction sites. Higher scores indicate greater pain intensity.

    Time frame: 24, 48, and 72 hours after tooth extraction

  3. Postoperative analgesic consumption

    Postoperative analgesic consumption was assessed by recording the number of analgesic tablets taken for pain associated with each extraction site. Participants recorded analgesic use separately for the TXA-modified L-PRF and absorbable gelatin sponge sites. A higher number of tablets indicates greater analgesic consumption.

    Time frame: 24, 48, and 72 hours after tooth extraction

06

Study locations

1 site
  • Sivas Cumhuriyet University Faculty of Dentistry
    Sivas, Sivas 58000, Turkey (Türkiye)
07

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because no IPD sharing plan was established for this study.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07830875
Lead sponsor
Cumhuriyet University
Responsible party
Merve Yiğit (Research Assistant, Cumhuriyet University) — Principal investigator
First posted
Sep 21, 2026
Start date
Aug 1, 2025
Primary completion
Jan 5, 2026
Completion
Jan 5, 2026
Last update
Sep 23, 2026

Study contacts

Abdullah İ Özeç, PhD
study director · Sivas Cumhuriyet University, Faculty of Dentistry, Department of Oral and Maxillofacial Surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion